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ABSTRACT
Objective: To identify the metabolic signature of the various levels of cognitive deficits in amyo-
trophic lateral sclerosis (ALS) using 18F-2-fluoro-2-deoxy-D-glucose-PET (18F-FDG-PET).
Methods: A total of 170 ALS cases consecutively enrolled at the ALS Center of Turin underwent
brain 18F-FDG-PET and were classified as displaying normal cognition (ALS-Cn; n 5 94),
full-blown frontotemporal dementia (ALS-FTD; n 5 20), executive or nonexecutive cognitive
impairment not fulfilling FTD criteria (ALS-Ci; n 5 37), prevalent behavioral changes (n 5 9), or
nonclassifiable impairment (n 5 10) according to neuropsychological testing. Group comparisons
of 18F-FDG-PET pattern were carried out among the cognitive subgroups.
Results: We found a significantly reduced frontal and prefrontal metabolism in ALS-FTD as com-
pared to ALS-Cn, while ALS-Ci showed an intermediate metabolic behavior in frontal cortex,
being hypometabolic as compared to ALS-Cn, and relatively hypermetabolic as compared to
ALS-FTD. Hypometabolism in frontal regions was associated in all comparisons to hypermetabo-
lism in cerebellum, midbrain, and corticospinal tracts: the more severe the cognitive decline, the
larger the size of the cluster and the statistical significance of 18F-FDG uptake differences.
Conclusions: This study demonstrated in a large cohort of patients with ALS a continuum of fron-
tal lobe metabolic impairment reflecting the clinical and anatomic continuum ranging from pure
ALS, through ALS with intermediate cognitive deficits, to ALS-FTD, and showing that patients
with intermediate cognitive impairment display a characteristic metabolic pattern. Since
18F-FDG-PET allows us to estimate the cerebral lesion load in vivo in neurodegenerative diseases,
it might be helpful to investigate in ALS its association with neuropsychological testing along the
disease course to disclose the early metabolic signature of possible cognitive impairment.
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GLOSSARY
18F-FDG-PET 5 18F-2-fluoro-2-deoxy-D-glucose-PET; ALS 5 amyotrophic lateral sclerosis; ALS-Bi 5 amyotrophic lateral
sclerosis with behavioral impairment; ALS-Ci 5 amyotrophic lateral sclerosis with cognitive impairment; ALS-Cn 5 amyo-
trophic lateral sclerosis with normal cognition; ALS-Nc 5 amyotrophic lateral sclerosis with nonclassifiable cognitive impair-
ment;ALSFRS-R5Amyotrophic Lateral Sclerosis Functional Rating Scale–revised;DSM-IV-TR5Diagnostic and Statistical
Manual of Mental Disorders, 4th edition, text revision; FTD5 frontotemporal dementia; FTLD5 frontotemporal lobar degen-
eration; pTDP-43 5 phosphorylated TDP-43.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the adult life affecting
upper and lower motor neurons involving bulbar and spinal regions, characterized by progressive
muscle weakness and wasting and limb spasticity. Besides motor impairment, extramotor abnor-
malities in ALS may include cognitive and behavioral changes falling within the frontotemporal
lobar degeneration (FTLD) spectrum. Overall,;15% of patients with ALS display a full-blown
frontotemporal dementia (FTD), while;35% have more subtle cognitive alterations involving
executive and nonexecutive domains.1,2
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18F-2-fluoro-2-deoxy-D-glucose-PET (18F-
FDG-PET) studies have shown hypometa-
bolic clusters in frontal and temporal cortex
as neurobiological correlates of ALS with
comorbid FTD.3 Moreover, 2 recent studies
have shown that 18F-FDG-PET can discrimi-
nate patients with ALS from healthy controls
with accuracy close to 94%.4,5
Some studies reported a gradient of increas-
ing brain atrophy assessed through structural
MRI along the ALS-FTD continuum, ranging
from pure ALS, through ALS with cognitive or
behavioral deficits, to ALS with frank FTD.6,7
However, it is still unclear whether the clinical
entities of such disease spectrum have distinct
metabolic correlates reflecting the different
degrees of cognitive impairment.
The aim of this study was to identify the
metabolic signature of the various levels of
cognitive deficits in ALS using 18F-FDG-PET.
METHODS Patients. A total of 170 patients with ALS who
agreed to undergo both neuropsychological assessment and
18F-FDG-PET were consecutively enrolled at the Turin ALS
Center, Italy. All patients fulfilled the El Escorial Revised Diagnos-
tic Criteria for definite, probable, or probable laboratory-supported
ALS.8 Patients were recruited at the time of diagnosis or during the
first follow-up visit (2months later). Neuropsychological evaluation
and 18F-FDG-PET were always performed within 1 month of each
other and within 12 months from ALS diagnosis. Respiratory
function was assessed for every subject within 4 weeks before or
after neuropsychological evaluation and 18F-FDG-PET. At the time
of assessments, none of the patients showed oxygen saturation
,92% at pulse oximetry. Patients with a history of neurologic
disorders affecting cognition (major stroke, severe head injuries,
mental retardation), alcohol and drug dependence, severe mental
illness, or use of high-dose psychoactive medications were not
enrolled in the study, nor were patients whose mother tongue
was not Italian.
Neuropsychological assessment. The selection of the neuro-
psychological tests, evaluating executive function, memory, visu-
ospatial function, and language, was based on the Clinical Diagnostic
Criteria for Frontotemporal Lobar Degeneration9 and the ALS-FTD
Consensus Criteria.10 Non-FTD dementias were diagnosed according
to the criteria of theDSM-IV-TR11 and those of the National Institute
of Neurological and Communicative Disorders and Stroke–
Alzheimer’s Disease and Related Disorders Association.12 The
neuropsychological battery included the following: Mini-Mental
State Examination, Wisconsin Card Sorting Test, Trail-Making
Test A and B, Stroop Color-Word Interference Test, letter and
category fluency test, Wechsler Memory Scale II–revised (Form 2),
Rey-Osterrieth Complex Figure Test, Token Test, Wechsler Adult
Intelligence Scale revised, Raven’s Progressive Colored Matrices, and
Frontal Assessment Battery. Neurobehavioral dysfunction was
assessed through the direct observation and the patient’s history,
and with the Frontal Systems Behavior Scale, using the family form
compiled by a close relative. The evaluation of anxiety and depression
was based on the Hospital Anxiety and Depression Scale. Further
details about the neuropsychological battery and the testing procedure
have been reported elsewhere.2
Cognitive classification. Clinical diagnosis and cognitive clas-
sification were obtained by neurologists and neuropsychologists
expert in ALS and FTD. Patients were subdivided into the follow-
ing 5 cognitive groups:
1. ALS with normal cognition (ALS-Cn).
2. ALS cases fulfilling the diagnostic criteria for FTD (ALS-FTD).
3. ALS cases with cognitive impairment not meeting the criteria
for FTD, but presenting impairment in 2 tests for executive
functions or in 2 tests for nonexecutive abilities (ALS-Ci).
4. ALS cases not meeting the criteria for FTD, with prevalent
behavioral impairment and presenting deficit in none or only
one executive test and no impairment in nonexecutive
domains (ALS-Bi).
5. ALS with nonclassifiable cognitive impairment (ALS-Nc),
including patients displaying deficits in one executive or one
nonexecutive test, sometimes associated with smooth behav-
ioral changes.
ALS-Nc cases were excluded from subsequent analyses
because the classification of this group as a distinct entity remains
unclear.
18F-FDG-PET. 18F-FDG-PET was performed according to pre-
viously published guidelines.13 PET/CT images were acquired by
a Discovery ST-E System (General Electric; Fairfield, CT). CT
scan of the brain (thickness 3.75 mm, 140k V, 60–80 mA/s) was
followed by PET brain scan (1 field of view of 30 transaxial
centimeters). Data were collected in 128 3 128 matrices; the
reconstructed voxel was 2.34 3 2.34 3 2.00 mm.
Group comparison. Clinical characteristics of patients belong-
ing to different categories were compared using x2 (discrete var-
iables) or Student t test/analysis of variance (continuous
variables). Data were analyzed using SPSS 21.0 statistical package
(SPSS Inc., Chicago, IL). Detailed methods of group comparison
of 18F-FDG-PET data are provided elsewhere.14 Preprocessing
and statistical analyses were performed by SPM8 implemented
in Matlab, 7.10.0. Scans were normalized by a 18F-FDG-PET
customized brain template, created at the same center and set
up equally to the SPM8 default one. Group comparisons were
carried out among ALS-Cn (n 5 94), ALS-FTD (n 5 20), ALS-
Ci (n5 37), and ALS-Bi (n5 9) by the 2-sample t test model of
SPM8, considering sex, type of onset, and age at PET as nuisance
variables. The p , 0.001 threshold was used to create statistical
parametric mapping t maps at peak and cluster level and the
threshold of p , 0.05 corrected for multiple comparisons by
false discovery rate was considered to be significant. If significant
clusters were not found, the more liberal threshold at p , 0.001
uncorrected for multiple comparisons was considered. The
coordinates of SPM isocenters were corrected by the subroutine
implemented by Matthew Brett (http://brainmap.org/index.html)
to match the Talairach coordinates. Brodmann areas were limited at
a range of 0–3 mm and identified by Talairach client (http://www.
talairach.org/index.html).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the institutional ethical
committee of the Turin ALS Centre. All patients provided writ-
ten informed consent before enrollment. Data were kept accord-
ing to the Italian law for the protection of privacy.
RESULTS Clinical data. The clinical features of pa-
tients included in the analysis are summarized
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in table 1. We found no difference in sex, site of onset
(bulbar/spinal), mean age at time of PET, mean time
from diagnosis to PET scan, and Amyotrophic Lateral
Sclerosis Functional Rating Scale–revised (ALSFRS-R)
total score among groups.
Group comparison of 18F-FDG-PET data. ALS-Cn vs ALS-
FTD. Patients with ALS-FTD showed a large cluster
of relative hypometabolism at p , 0.05corrected (fig-
ure, A, table 2) including bilateral premotor, frontal,
and anterior prefrontal cortex with left predominance
as well as left lateral prefrontal (Broca area) and orbi-
tofrontal cortex. Large regions with relative increased
metabolism in ALS-FTD were found at the same
threshold in cerebellum, midbrain, and corticospinal
tracts, bilaterally (figure, B).
ALS-Cn vs ALS-Ci. In ALS-Ci at p, 0.001uncorrected
a relative hypometabolic cluster in right anterior cin-
gulate, frontal and prefrontal cortex, as well as in left
prefrontal cortex (figure, C, table 2) and a relative
hypermetabolic cluster including midbrain and corti-
cospinal tracts bilaterally were found (figure, D).
ALS-Ci vs ALS-FTD. Relative hypometabolism was
found at p , 0.001uncorrected in ALS-FTD in left
orbitofrontal, prefrontal, and lateral frontal (Broca
area) cortex (figure, E, table 2). Also in this compar-
ison the most cognitively impaired group (ALS-FTD)
showed a relative hypermetabolism in cerebellum,
midbrain, and corticospinal tracts bilaterally at p ,
0.001uncorrected (figure, F).
No difference at the set statistical threshold was
found between ALS-Bi and any other group.
DISCUSSION This study analyzed the metabolic cor-
relates of the different degrees of cognitive impairment
in patients with ALS. We identified a decreasing gradi-
ent of frontal lobe metabolism going from ALS with
normal cognition to ALS with FTD, through cases with
intermediate cognitive deficits (ALS-Ci). According to
these findings, ALS-Ci seems to represent a discrete
category, showing less severe cognitive deficits and a
distinct metabolic pattern as compared to ALS-FTD,
being intermediate between pure ALS and ALS-FTD.
The groups with different degrees of cognitive
impairment did not significantly differ in sex distribu-
tion, site of onset, mean age at PET examination, mean
time from diagnosis to PET scan, or total ALSFRS-R
score. However, we included these variables as nui-
sance in the 18F-FDG-PET analyses and their contri-
bution to data variability was kept under control.
We found a significantly reduced frontal and pre-
frontal metabolism in the ALS-FTD group as com-
pared to patients with normal cognitive status.
Furthermore, ALS-Ci showed in frontal cortex an
intermediate metabolic behavior, being hypometa-
bolic as compared to ALS-Cn, and demonstrating a
cluster of higher relative metabolism as compared to
ALS-FTD. Such cluster was included in the same left
frontal regions found to be more severely hypometa-
bolic in ALS-FTD as compared to ALS-Cn, suggest-
ing a continuum between cognitive decline and
metabolic activity in these areas. This finding is con-
sistent with cognitive classification criteria and high-
lights the distinct metabolic pattern of ALS-Ci.
Our findings are in keeping with MRI studies
comparing patients with ALS with different levels of
cognitive impairment. A structural MRI study on
39 ALS cases reported that patients with ALS-FTD
display significantly more atrophy of prefrontal and
anterior temporal cortex as compared to patients with
ALS with cognitive and behavioral symptoms not ful-
filling FTD criteria (ALS-plus) and that the ALS-plus
group shows significantly more atrophy than the pure
ALS group in various areas including the superior
frontal gyrus and the left planum temporale, support-
ing the hypothesis of a gradient of atrophy across
groups.6 Another MRI study showed that both pa-
tients with ALS-FTD and patients with ALS with
cognitive impairment display cortical thinning of
bilateral frontal and temporal cortex, with a more
pronounced atrophy in the former group, suggesting
the concept of a morphologic continuum reflecting
the clinical one.7
A possible advantage of 18F-FDG-PET as com-
pared to structural MRI is that abnormalities of
Table 1 Clinical characteristics of patients according to cognitive categories
ALS-Cn (n 5 94) ALS-FTD (n 5 20) ALS-Ci (n 5 37) ALS-Bi (n 5 9) Total (n 5 160) p Value
Male/female 61/33 13/7 19/18 4/5 97/63 0.38
Onset, bulbar/spinal 31/63 12/8 13/24 4/5 60/100 0.21
Mean (SD) age at PET, y 62.1 (11.5) 64.4 (12) 68.4 (8.4) 66.3 (9.8) 63.9 (10.9) 0.07
Mean (SD) time diagnosis to PET, mo 6.4 (3.2) 7.1 (4.3) 6.1 (4.9) 5.5 (3.2) 6.3 (4.1) 0.65
Mean (SD) ALSFRS-R total score 39.8 (6.2) 37.2 (5.5) 39.6 (4.3) 35.7 (7.4) 39.31 (6.1) 0.24
Abbreviations: ALS-Bi 5 amyotrophic lateral sclerosis with behavioral impairment; ALS-Ci 5 amyotrophic lateral sclerosis with cognitive impairment; ALS-
Cn 5 amyotrophic lateral sclerosis with normal cognition; ALS-FTD 5 amyotrophic lateral sclerosis with frontotemporal dementia; ALSFRS-R 5 Amyotro-
phic Lateral Sclerosis Functional Rating Scale–revised.
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cortical metabolism may precede gray matter atrophy
and therefore may be identified earlier along the dis-
ease course. This concept is supported by a study
comparing brain structural MRI and metabolic
18F-FDG-PET changes in brain gray matter of pa-
tients with ALS-FTD, showing metabolic alterations
in most of the brain regions displaying structural
changes but also isolated 18F-FDG uptake reduction
in some other areas.15
In our study, hypometabolism in frontal regions
was associated in all comparisons to hypermetabolism
in cerebellum, midbrain, and corticospinal tracts: the
more severe the cognitive decline, the larger the size of
the cluster and the statistical significance of 18F-FDG
uptake differences (figure, B, D, and F). This finding
supports the hypothesis that astrocytosis, mainly in
white matter, is associated with ALS neurodegenera-
tion and possibly anticipates cortical changes.14,16–18
Overall, our results support the notion that patients
with ALS with cognitive impairment not fulfilling
FTD criteria represent a distinct category with a pecu-
liar metabolic pattern placed between the 2 extremities
of the ALS-FTD spectrum. This point is of outstand-
ing importance, since the commixture of pure ALS
cases with patients with ALS with cognitive deficits
without frank FTD might produce inconsistent find-
ings in the research on structural and functional corre-
lates of cognitive impairment in ALS.6
A neuropathologic staging system of the spreading of
brain pathology in ALS has been proposed, based on the
propagation of phosphorylated TDP-43 (pTDP-43)
proteinopathy, since pTDP-43 aggregates seem to be
strictly linked to neuron degeneration.19 According to
this model, pTDP-43 necessarily tends to spread with
disease progression via axonal transport from the primary
motor cortex to the prefrontal areas, suggesting that all
patients with ALS are susceptible to develop frontal cog-
nitive impairment over time, according to disease dura-
tion and rate of progression. 18F-FDG-PET is a measure
of neuronal injury and degeneration in vivo,20 allowing
prospective studies, unlike neuropathology. Therefore,
functional neuroimaging might enrich neuropsycholog-
ical testing in the longitudinal evaluation of cognitive
impairment in ALS, providing early information on
the spreading of brain pathology along disease
progression.
Possible limitations of this study should be consid-
ered. First, we have no longitudinal data on brain
metabolism in ALS-Ci patients. The area of the course
of cognitive impairment over time in ALS remains
largely unexplored. A few longitudinal studies with
small sample size showed a limited, if any, deteriora-
tion of cognitive performance over time.21–25 A recent
larger population-based longitudinal study reported
that patients with ALS displaying normal cognition
at diagnosis tend to remain cognitively intact over time
Figure 18F-FDG-PET data: Group comparison
(A, B) Amyotrophic lateral sclerosis with normal cognition (ALS-Cn) vs amyotrophic lateral
sclerosis–frontotemporal dementia (ALS-FTD). (C, D) ALS-Cn vs amyotrophic lateral sclero-
sis with cognitive impairment (ALS-Ci). (E, F) ALS-Ci vs ALS-FTD. (A, C, E) Clusters of relative
hypometabolism. (B, D, F) Clusters of relative hypermetabolism.
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and that, in the absence of minimal alteration at base-
line, executive dysfunction may arise in very late stages,
if at all. Otherwise, patients with early executive or
nonexecutive cognitive change may show a certain
degree of spreading of cognitive impairment.26 Second,
we did not evaluate the possible role of cognitive
reserve, a concept that has been proved to be valid
for dementias other than frontotemporal syndromes
related to ALS and that aims at explaining the possible
mismatch between cerebral lesion load and clinical
deficits we sometimes observe in clinical practice.
Third, we could not characterize the metabolic pattern
of ALS-Bi and ALS-Nc, because of the small size of
these cognitive subgroups in our sample. On the other
hand, a notable strength of this work is the high sample
size (n 5 170), making it the largest survey on ALS
including both neuropsychological assessment and
18F-FDG-PET performed so far.
This study found in a large ALS cohort that frontal
lobe metabolic impairment reflects the clinical and
functional continuum ranging from ALS with normal
cognition, through ALS with subtle, intermediate
cognitive deficits, to ALS with comorbid FTD, and
showed that patients with intermediate cognitive
impairment display a characteristic metabolic pattern.
18F-FDG-PET is considered a valuable tool to esti-
mate the cerebral lesion load in vivo in neurodegen-
erative diseases. Our data indicate that it might be
helpful to investigate the neurobiological basis of cog-
nitive impairment in ALS along the disease course,
since it can show the early regional spreading of brain
metabolic alterations.
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